loading

INVITRO INTERNATIONAL REPORTS THIRD QUARTER RESULTS

Company Announces Lowest Quarterly Loss and Expands Merger Options
Irvine, CA, August 15, 1997 — InVitro International (Symbol INVI) today reported results for its third quarter ended June 30, 1997. The net loss for the quarter was $198,000 ($0.02 per share), a 42% decrease compared to $341,000 ($0.03 per share) reported for the same period last year. Revenues for the quarter were $181,000 compared to $327,000 for the same quarter in fiscal 1996.

On Friday, June 13, 1997, the U.S. Environmental Protection Agency (EPA) issued the final approval for CORROSITEX® in the Federal Register as Solid Waste Method 1120. This method lists CORROSITEX as an approved test for characterizing dermal corrosivity for solid waste (40 CFR Parts 260, 264, 265, and 266). CORROSITEX is an in vitro test system that mimics the effect of corrosives on living skin while lowering testing costs and providing quicker results when compared to in vivo.

During the first five months of 1997, the Company announced it had entered into letters of intent to pursue merger negotiations with two other business entities. Negotiations as to the first proposed merger were terminated by mutual agreement and activities relating to a proposed merger with Miragen Inc. have been suspended unless Miragen obtains additional financing.

The Company’s management is currently negotiating a proposed merger with another business engaged primarily in the development and sale of natural gas resources, but a definitive merger proposal has not been executed. Management plans to pursue merger negotiations with any suitable prospective candidate.

The Company’s management anticipates that existing cash resources of InVitro are adequate to sustain its current business operations only through the end of September 1997, and that increases in internal sales revenue and /or additional capital investment, neither of which can be predicted at present, will be required for InVitro to have sufficient resources to sustain its operations thereafter. The Company’s management has determined that InVitro will be forced to cease active business operations, other than ongoing efforts to market Guardian DNA products held in inventory, should the Company fail to enter into a letter of intent or other agreement to merge with another business enterprise by approximately the end of August 1997.

InVitro International is engaged in the development, manufacture and sale of quality, proprietary preventive products and services to ensure the safekeeping of humans and the environment, and to minimize animal testing in commercial and academic enterprise.

The statements made in this press release contain certain forward looking statements within the meaning of section 27a of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934 that involve a number of risks and uncertainties, including the risk that InVitro may be unable to complete the proposed transaction. Actual events or results may differ from InVitro’s expectations. In addition, investors should be apprised of risk factors discussed from time to time in the Company’s filings with the Securities and Exchange Commission, including without limitation information set forth in Exhibit 99.1 filed with the Company’s Annual Report on Form 10-KSB for the fiscal year ended September 30, 1996.

INVITRO INTERNATIONAL REPORTS SECOND QUARTER RESULTS

Company Signs Merger Letter Of Intent With Miragen
Irvine, CA, May 15, 1997 — InVitro International (Symbol INVI) today reported results for its second quarter ended March 31, 1997. Revenues for the quarter were $164,000 compared to $260,000 for the same quarter in fiscal 1996. The net loss for the quarter declined by 15% to $395,000 ($0.02 per share), compared to $467,000 ($0.04 per share) reported for the same period last year.

“Despite disappointing core business sales results, we remain encouraged by the prospects for Guardian DNAÔ ,” said W. Richard Ulmer, president and CEO for InVitro International. Guardian DNA is the new three-part infant/child safety system that is visioned as a hospital replacement for newborn footprinting; it combines education, documentation and ultimately identification using DNA technology. “Several healthcare institutions are in the process of reviewing Guardian, and/or obtaining the necessary internal approvals, for possible implementation at their respective facilities,” Ulmer added.

On Tuesday, May 13, 1997, the Company signed a letter of intent to merge with Miragen, Inc. (Irvine, CA) in a transaction anticipated to provide current InVitro shareholders with 20% of the combined company’s common stock subject to certain adjustments based on business developments prior to a definitive agreement. The new merger opportunity immediately follows the end of negotiations with Shenyang International as a potential merger partner and is contingent upon due diligence examination (already in process), filing of the appropriate materials with the Securities and Exchange Commission and approval by the majority of InVitro shareholders, among other conditions. Assuming the proposed merger is successfully completed, the assets and business of Miragen will be acquired by InVitro and will include all of Miragen’s existing assets and proprietary rights relating to human and animal identification products and related technologies. “The synergy between the two companies is both financially and market-driven,” said Ulmer. “We believe that InVitro’s core technology combined with Miragen’s biological and identification products, which include Guardian DNA, address unique marketplaces, and allow us to provide better pricing opportunities to customers and prospects.”

At the close of business on Wednesday, May 14, 1997, InVitro’s securities were removed from The Nasdaq SmallCap Market for non-compliance with NASDAQ listing standards. The Company’s common stock will continue to be traded in the over-the-counter market and quoted on the NASD Electronic Bulletin Board.

Miragen develops, manufactures and sells biological identification and testing technologies used in hospitals, medical laboratories, animal identification, and forensics.

InVitro International is engaged in the development, manufacture and sale of quality, proprietary preventive products and services to ensure the safekeeping of humans and the environment, and to minimize animal testing in commercial and academic enterprise.

The statements made in this press release contain certain forward looking statements within the meaning of section 27a of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934 that involve a number of risks and uncertainties, including the risk that InVitro may be unable to complete the proposed transaction. Actual events or results may differ from InVitro’s expectations. In addition, investors should be apprised of risk factors discussed from time to time in the Company’s filings with the Securities and Exchange Commission, including without limitation information set forth in Exhibit 99.1 filed with the Company’s Annual Report on Form 10-KSB for the fiscal year ended September 30, 1996.

INVITRO INTERNATIONAL SIGNS MERGER LETTER OF INTENT

IRVINE, CA, March 3, 1997 — InVitro International (Nasdaq SmallCap Market Symbol “INVI”) today announced it has signed a letter of intent to merge with Shenyang International Inc. in a transaction where InVitro stockholders would retain 20% of the combined company’s common stock. The proposed transaction is subject, among other conditions, to additional due diligence investigations, approval by the board of directors for each of the parties, preparation and execution of a definitive merger agreement, filing and the effectiveness of a registration statement and proxy materials with the Securities and Exchange Commission, and approval by the majority vote of InVitro shareholders.

The Company currently anticipates the merger proposal will be presented to InVitro’s board for consideration before the end of March 1997.

Privately-held Shenyang International Inc. is a foreign holding company organized in the British Virgin Islands and owns 99% of ShenYang Holding Company (“SHC”). Organized in 1988 and based in the Liaoning Province of northeastern China, SHC operates four business divisions in mainland China with approximately 300 employees. SHC’s business operations include distribution of medical products, the manufacture and sale of computer systems, ownership and management of the Lan Hua Hotel in ShenYang city and development of international industrial trade. Among other products, SHC distributes medical scanning devices for General Electric and markets personal computer hardware and networking systems. SHC has operated profitably for the last five years, and its annual revenues have increased from $6.5 million in 1992 to more than $15 million currently.

InVitro International, organized in 1985, develops and markets proprietary in vitro assay systems to detect, predict and rank potential irritation and toxic levels of substances to humans and the environment and distributes child safety and identification products. Located in Irvine, California, the Company distributes its products throughout North America, Europe and the Pacific Rim. InVitro previously reported a net loss for the year ended September 30, 1996 of $1,899,000, or $.15 per share, on revenues of $1,063,000. Results for the most recent fiscal quarter ended December 31, 1996 were a net loss of $506,000, or $.04 per share, on $259,000 in net sales. At February 28, 1997, InVitro had 14,028,300 shares of common stock outstanding.

Assuming the proposed merger is successfully completed, InVitro has undertaken to reduce its existing business operations to eliminate negative cash flow and currently anticipates those operations will continue under the direction of InVitro’s management as a separate division or subsidiary of the combined enterprise.

The statements made in this press release contain certain forward looking statements within the meaning of section 27a of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934 that involve a number of risks and uncertainties, including the risk that InVitro may be unable to complete the proposed transaction. Actual events or results may differ from InVitro’s expectations. In addition, investors should be apprised of risk factors discussed from time to time in the Company’s filings with the Securities and Exchange Commission, including without limitation information set forth in Exhibit 99.1 filed with the Company’s Annual Report on Form 10-KSB for the fiscal year ended September 30, 1996.

INVITRO INTERNATIONAL REPORTS FIRST QUARTER RESULTS

Board Of Directors Defer Decision To Implement 1-For-10 Reverse Stock Split Recently Approved By Shareholders
IRVINE, CA, February 4, 1997 — InVitro International (NASDAQ Small Cap; INVI) today reported results for its first quarter ended December 31, 1996. Revenues for the quarter were $259,000 compared to $225,000 for the first quarter of the prior year, a 15% increase. The net loss for the current quarter was $506,000 or $.04 per share, compared to a net loss of $522,000 or $.04 per share reported for the same period of the previous year.

During its Annual Shareholders Meeting held on Friday, January 31, 1997, the Company also announced its Board will delay a decision whether and when to implement a 1-for-10 reverse stock split authorized at the meeting by a majority of shareholders. InVitro International’s Board of Directors will defer an implementation decision until the timing of revised NASDAQ rules are announced and the Board has had an opportunity to assess initial results from the GiftPax program for Guardian DNA. (Guardian DNA is the new three-part infant/child safety system being marketed directly to 3.7 million new mothers during calendar year 1997 via GiftPax/American Sampling, Inc.) “We should have a preliminary indication as to the level of sales we can expect from the GiftPax opportunity by the end of March,” stated W. Richard Ulmer, President and CEO for InVitro International.

InVitro International is engaged in the development, manufacture and sale of quality, proprietary preventive products and services to ensure the safekeeping of humans and the environment, and to minimize animal testing in commercial and academic enterprise.

Except for the historical information contained herein, the matters discussed in this news release are forward looking statements that involve risks and uncertainties, including the acceptance of new products, the impact of competitive products and pricing, and the management of growth. Please refer to the Company’s filings with the Securities and Exchange Commission for a summary of cautionary statements.

INVITRO INTERNATIONAL TO REACH NEARLY 4 MILLION NEW MOTHERS IN 1997 WITH GUARDIAN DNA

$1.8 Million In INVI Sales To Result From Every 1 Percent Who Decide To Buy
IRVINE, CA, December 18, 1996 — InVitro International (NASDAQ Small Cap; INVI) today reported results of operations for its fiscal year ended September 30, 1996. The net loss for fiscal 1996 was $1,899,000 ($0.15 per share) on revenues of $1,063,000 versus a net loss of $2,763,000 ($0.23 per share) on revenues of $1,137,000 in fiscal 1995, and is the lowest in the Company’s public history. Progress with regard to net financial results are attributable to cost controls implemented throughout the fiscal year, while maintaining fiscal 1995 sales levels.

President and CEO for InVitro International, W. Richard Ulmer stated “We are encouraged that annual sales remained virtually the same and that losses declined by nearly $1 million, despite the heavy fourth quarter investment to introduce Guardian DNAä, the new infant/child safety system. We remain enthusiastic regarding future prospects for Guardian and are pleased that our core technology has recently attracted several new and important customers, including Ingman Laboratories in Minneapolis, Minnesota and Sima-Labs International in Merrillville, Indiana. Additionally, InVitro recently installed its IrritectionÒ Assay System in two textile companies, one of which carries world-wide name recognition.”

The goal of Company-wide profitability previously forecasted for InVitro’s first quarter of fiscal 1997 will not be met. The delay is a function of the difficulty in predicting the timing and the level of acceptance for Guardian DNA. As reported earlier, the Company has teamed with GiftPax/American Sampling, Inc. to provide approximately 3.7 million new mothers during 1997 with information about Guardian DNA during their hospital stay and the ability to purchase it at a reduced price. The first shipment of redeemable Guardian brochures were delivered to hospitals nationwide in early December and the product fulfillment center is ready to begin processing orders. “We feel extremely confident that Guardian DNA will be a success as it reaches hundreds of thousands of new mothers in January, and each successive month throughout 1997,”remarked Ulmer. “We estimate that a mere 1% response rate over the course of the next 12 months will turn the corner for the Company financially. Given the positive acceptance levels predicted by internal market research among end users, we have every reason to remain excited.”

InVitro International is engaged in the development, manufacture and sale of quality, proprietary preventive products and services to ensure the safekeeping of humans and the environment, and to minimize animal testing in commercial and academic enterprise.

Except for the historical information contained herein, the matters discussed in this news release are forward looking statements that involve risks and uncertainties, including the acceptance of new products, the impact of competitive products and pricing, and the management of growth. Please refer to the Company’s filings with the Securities and Exchange Commission for a summary of cautionary statements.